Labcorp — Apr 29, 2025 release

(4) Adjusted operating income and margin increased due to organic demand and LaunchPad savings, partially offset by higher personnel costs. As of March 31, 2025 Metrics Summary (Dollars in billions) TTM Net Orders $ 3.15  TTM Book to Bill 1.07  Backlog $ 8.18  (5) Next Twelve Months Forecast Backlog Conversion $ 2.56  (5) Backlog increased 3.5% compared to this period last year. 6 Guidance for 2025 Labcorp is updating 2025 full year guidance to reflect its first quarter performance and full year outlook. The following guidance assumes foreign exchange rates effective as of March 31, 2025, for the remainder of the year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends. (Dollars in billions, except per share data) Previous Updated Results 2025 Guidance 2025 Guidance 2024 Low High Low High Revenue Labcorp Enterprise (1)(2) $13.01 6.7% 8.0% 6.7% 8.0% Diagnostics Laboratories (3) $10.14 6.5% 7.7% 6.5% 7.7% Biopharma Laboratory Services (4) $2.92 3.0% 5.0% 3.0% 5.0% Adjusted EPS $14.57 $15.60 $16.40 $15.70 $16.40 Free Cash Flow $1.10 $1.10 $1.25 $1.10 $1.25 (1) 2025 Guidance includes an impact from foreign currency translation of (0.2%). (2) Enterprise level revenue is presented net of intersegment transaction eliminations. (3) 2025 Guidance includes an impact from foreign currency translation of (0.2%). (4) 2025 Guidance includes an impact from foreign currency translation of (0.3%). 7 Use